{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T04:24:03Z","timestamp":1764044643954},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Sylvester Comprehensive Cancer Center"},{"name":"CDMRP Ovarian Cancer","award":["W81XWH-18-1-0072","NIMHD L60MD014321"],"award-info":[{"award-number":["W81XWH-18-1-0072","NIMHD L60MD014321"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ygyno.2020.08.030","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T03:52:33Z","timestamp":1600401153000},"page":"554-562","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population"],"prefix":"10.1016","volume":"159","author":[{"given":"Scott E.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Sanchez","family":"Covarrubias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Siemon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Matt","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Schlumbrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia HL","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.08.030_bb0005","series-title":"Cancer Facts and Figures 2020","author":"American Cancer Society","year":"2020"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11912-008-0078-8","article-title":"Low-grade serous ovarian cancer: a unique disease","volume":"10","author":"Schmeier","year":"2008","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0020","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.1521","article-title":"In ovarian neoplasms, BRAF, but not KRAS mutations are restricted to low grade serous tumours","volume":"202","author":"Sieben","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0035","series-title":"Presented at 2019 ESMO Congress; Sept 27-Oct 2, 2019; Barcelona, Spain. Abstract LBA62","article-title":"A randomized phase II\/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer","author":"Gershenson","year":"2020"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0050","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0055","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2019.12.041","article-title":"Disparities in care among patients with low-grade serous ovarian carcinoma","volume":"157","author":"Siemon","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0065","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using at two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0070","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) \u2013 A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0080","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0085","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1002\/cncr.25929","article-title":"Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma","volume":"117","author":"Schlumbrecht","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2016.08.320","article-title":"Low grade serous ovarian cancer: a review","volume":"143","author":"Kaldawy","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0095","doi-asserted-by":"crossref","first-page":"37663","DOI":"10.18632\/oncotarget.5438","article-title":"Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes","volume":"6","author":"Hunter","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-020-0803-0","article-title":"Smoking, alcohol consumption and colorectal cancer risk by molecular pathological subtypes and pathways","author":"Amitay","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0105","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4103\/IJPM.IJPM_80_19","article-title":"Biomarker for colorectal carcinoma -ERCC1-New kid on the block","volume":"62","author":"Bansal","year":"2019","journal-title":"Indian J. Pathol. Microbiol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0110","doi-asserted-by":"crossref","first-page":"E3205","DOI":"10.3390\/molecules23123205","article-title":"Function and interactions of ERCC1-XPF in DNA damage response","volume":"23","author":"Faridounnia","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0115","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/cancers11081149","article-title":"ERCC1 is a predictor of anthracycline resistance and taxane sensitivity in early stage or locally advanced breast cancers","volume":"11","author":"Abdel-Fatah","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0120","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.4238\/2014.May.9.15","article-title":"Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy","volume":"13","author":"Wang","year":"2014","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cm.10116","article-title":"\u03b2-tubulin in human development and cancer","volume":"55","author":"Katsetos","year":"2003","journal-title":"Cell Motil. Cytoskeleton"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0130","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.3390\/ijms20163936","article-title":"TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer","volume":"20","author":"Sekino","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0135","article-title":"Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: is it time to move forward?","volume":"7","author":"Shayna","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0140","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/bjc.2011.129","article-title":"Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer","volume":"104","author":"Takezawa","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0145","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s12094-014-1258-7","article-title":"The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer","volume":"17","author":"Kim","year":"2015","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0150","article-title":"Comparison of Nanostring nCounter\u00ae Data on FFPE Colon cancer samples and affymetrix microarray data on matched frozen tissues","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3322\/caac.21560","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","volume":"69","author":"El-Deiry","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.08.030_bb0160","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12864-019-5849-0","article-title":"Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series","volume":"20","author":"Picornell","year":"2019","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1261\/rna.034710.112","article-title":"Systematic evaluation of medium-throughput mRNA abundance platforms","volume":"19","author":"Prokopec","year":"2013","journal-title":"RNA"},{"key":"10.1016\/j.ygyno.2020.08.030_bb0170","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820338312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820338312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T08:05:05Z","timestamp":1715846705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820338312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0090825820338312"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.030","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}